What Is BPC-157
BPC-157 (sequence GEPPPGKPADDAGLV, molecular weight 1419) is a fifteen-amino-acid peptide derived from the so-called body protection compound, a protein present in human gastric juice. Its defining characteristic is high stability — unlike most peptides, it resists enzymatic digestion and remains functional directly in the gastric environment, which is also why it was originally studied in relation to the digestive tract.
In development, BPC-157 was carried by the Croatian pharmaceutical company Pliva under the code name PL 14736 as a candidate for treating inflammatory bowel disease, specifically ulcerative colitis. It was under this designation that it went through the only published human clinical studies to date, described below.
How BPC-157 Works
According to published work, BPC-157's mechanism of action isn't yet fully clarified, but research points to several concurrent pathways. The peptide influences the nitric oxide (NO) system and the VEGF/VEGFR2 pathway (vascular endothelial growth factor and its receptor), which manifests as support for angiogenesis — the formation of new blood vessels at the site of injury. In cell studies on tendon fibroblasts, BPC-157 increases expression of the growth hormone receptor, amplifying growth hormone's effect on cell proliferation, and activates the FAK-paxillin signaling pathway associated with cell migration and survival. The peptide also has anti-inflammatory effects — in preclinical models it reduces levels of pro-inflammatory cytokines.
This combination of mechanisms — supporting blood vessel formation, influencing growth hormone activity at the tissue level, and an anti-inflammatory effect — is the main reason BPC-157 is studied across such a wide range of tissues: tendons, ligaments, muscle, bone, skin, cornea, and the digestive tract.
An interesting feature of BPC-157 is its pharmacokinetic profile — it breaks down in the body relatively quickly, with a half-life under 30 minutes, is metabolized in the liver, and excreted by the kidneys. A short half-life in a peptide that, according to preclinical data, is meant to influence tissue regeneration over days to weeks suggests the mechanism likely doesn't rely on the compound remaining in circulation long-term, but rather on the peptide kicking off a cascade of cellular processes (blood vessel formation, fibroblast activation, growth hormone signaling) that continue after it has been cleared. Exactly how a short-lived molecule triggers the longer-lasting biological effect seen in studies isn't yet satisfactorily explained in the available literature.
What Preclinical Studies Show
The vast majority of data on BPC-157 comes from animal experiments (most often in rats) and cell cultures. This preclinical data is extensive and fairly consistent across different tissue types.
| Tissue Type / Model | Experimental Model | Key Finding |
|---|---|---|
| Achilles tendon | Transected Achilles tendon in rats | Accelerated healing, better collagen organization, faster recovery of mechanical strength (one study reported roughly 30–50% faster load-to-failure recovery vs. controls) |
| Muscle | Crushed/transected quadriceps in rats | Accelerated healing of muscle injury, improved functional recovery |
| Bone | Segmental bone defect in rabbits | Osteogenic effect comparable to bone marrow implantation or autologous bone tissue implantation |
| Digestive tract | Colocutaneous and ileoileal fistulas, anastomoses in rats | Accelerated healing of intestinal fistulas and joins, higher pressure required to induce leaking (better functional closure) |
| Tendon fibroblasts (in vitro) | Cell culture from rat Achilles tendon | Increased growth hormone receptor expression, higher cell migration and survival |
Toxicology studies in animals found no lethal dose (LD1), and the preclinical safety profile is, according to published work, favorable, with no major organ toxicity at the doses studied. That needs to be clearly separated from the question of safety in humans, however, where the picture is different — see the next section.
What Human Studies Show
Unlike the rich preclinical literature, the number of actual human clinical studies is very limited. A 2025 systematic review that screened the literature back to 1993 identified 544 articles on BPC-157, of which only 36 met inclusion criteria — and of those, 35 were preclinical, with only one being a clinical study.
| Study | Type and Population | Finding |
|---|---|---|
| Veljaca et al. (2003), Gut | First human study — safety, tolerability, and pharmacokinetics of PL 14736 (rectal administration) in healthy male volunteers | Administration was safe and well tolerated; opened the door to the subsequent randomized trial |
| Ruenzi et al. (2005), Gastroenterology | Multicenter, randomized, double-blind, placebo-controlled Phase II study — PL 14736 enema in patients with mild-to-moderate ulcerative colitis | The only published randomized controlled trial of BPC-157 in humans for this indication; further public clinical development under this designation did not continue |
| Retrospective clinical series (cited in the 2025 systematic review) | Intra-articular BPC-157 injection in patients with chronic knee pain | 7 of 12 patients reported relief lasting more than 6 months; this is an uncontrolled retrospective series (level IV–V evidence), not a randomized trial |
The authors of the 2025 systematic review put it plainly: preclinical data consistently supports a role for BPC-157 in healing fractures and tendon, ligament, and muscle injuries, but human clinical evidence remains sparse. In other words — the animal and cell data are extensive and encouraging, but they don't substitute for the randomized controlled human trials that are missing outside the narrow ulcerative colitis indication studied two decades ago.
Safety: What's Known and What Isn't
For the BPC-157 molecule itself, preclinical toxicology studies found no significant organ toxicity, and early human studies (the PL 14736 safety trial) rated administration as safe and well tolerated. However, the 2025 systematic review explicitly states that clinical human safety data is essentially lacking — what exists today is largely extrapolated from preclinical models plus one narrowly focused clinical trial.
A separate category of risk concerns the quality of products available outside the regulated pharmaceutical supply chain. The review's authors explicitly note that adverse effects in real-world users may stem from unregulated manufacturing, contamination, or unknown product purity — that is, from manufacturing and distribution factors, not necessarily from the BPC-157 molecule itself in a pure, correctly manufactured form.
Regulatory Status
BPC-157's regulatory situation has shifted in recent years and is still evolving, which is worth keeping in mind as a current, not a settled, state.
| Period | Regulatory Step | Significance |
|---|---|---|
| Late 2023 | The U.S. FDA placed BPC-157 into so-called Category 2 of the bulk drug substances list for compounding under Section 503A | Category 2 effectively barred compounding pharmacies from using BPC-157 in preparations due to safety concerns and lack of data |
| April 2026 | The FDA formally removed BPC-157 from Category 2 | Removal of the formal "significant safety risk" designation — but this is a procedural step, not an approval; it did not automatically grant BPC-157 authorization for compounding |
| July 2026 | FDA's Pharmacy Compounding Advisory Committee (PCAC) voted 8 to 6 to recommend adding BPC-157 to Category 1 | The recommendation is tied specifically to a proposed ulcerative colitis indication, not to general use; the vote is advisory only, and final FDA rulemaking had not concluded as of August 2026 |
Independent of this pharmaceutical regulatory track, BPC-157 is a banned substance in professional sports (WADA), so athletes should assume its use is monitored and sanctioned in competitive settings regardless of how its status evolves in the US.
Forms Used in Research
In laboratory settings, BPC-157 most commonly occurs as a lyophilized powder in injection vials, dissolved in a suitable solvent immediately before further experimental use — in published studies it has been administered parenterally (by injection), orally, or directly in drinking water in animal models, owing to the peptide's unusual stability even in the digestive tract. This sets it apart from many other peptides, which don't survive oral administration in active form.
Summary
BPC-157 is a gastric pentadecapeptide with extensive and fairly consistent preclinical evidence across the healing of tendons, ligaments, muscle, bone, and the digestive tract, supported by several concurrent mechanisms — promoting angiogenesis, influencing the growth hormone axis at the tissue level, and an anti-inflammatory effect. Human clinical evidence, however, is markedly thinner — limited to one safety study, one Phase II randomized trial in ulcerative colitis from the mid-2000s, and a small uncontrolled clinical series. Its US regulatory status shifted between 2023 and 2026 (compounding ban → removal from the restricted category → an ongoing review for an approved category tied to a specific indication) and remained unresolved as of August 2026. Anyone wanting to track further developments should watch the outcome of the FDA's ongoing Category 1 rulemaking process.
Sources
- Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, Apostolakos JM. "Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review." Sports Health, 2025.
- Ruenzi M, Stolte M, Veljaca M, Oreskovic K, Peterson J, et al. "A multicenter, randomized, double blind, placebo-controlled phase II study of PL 14736 enema in the treatment of mild-to-moderate ulcerative colitis." Gastroenterology, 2005.
- Veljaca M, Pavic Sladoljev D, Mildner B, et al. "Safety, tolerability and pharmacokinetics of PL 14736, a novel agent for treatment of ulcerative colitis, in healthy male volunteers." Gut, 2003.
- Sikiric P, et al. "Focus on ulcerative colitis: stable gastric pentadecapeptide BPC 157." Review, 2011–2012.
- "From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management." International Journal of Molecular Sciences, 2026.
- U.S. Food and Drug Administration — Bulk drug substances list under Section 503A (Category 1/Category 2), 2023–2026 updates.